Around the Region

Latest studies support Tysabri

Biogen Idec Inc.’s multiple sclerosis drug Tysabri performed well in studies that compared it to other treatments on the market, according to the Weston biotechnology company and its Irish partner in Tysabri, Elan PLC.

In particular, the results showed patients taking the drug who contract a rare brain disease — called progressive multifocal leukoencephalopathy — have a much better chance of recovering if the condition is detected earlier.


Details from the studies will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego.

“These new data reinforce our belief in the substantial efficacy­ Tysabri has demonstrated at both the early and advanced stages of relapsing forms of MS,” said Alfred Sandrock, Biogen Idec’s chief medical officer.

Globe Staff

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of